KemPharm Inc

We employ our Ligand Activated Therapy (LAT) platform technology to create prodrugs in order to improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

Our most advanced product candidate, KP201/APAP, consists of KP201, our prodrug of hydrocodone, formulated in combination with acetaminophen (APAP). We are developing KP201/APAP as an immediate release (IR) product candidate for the treatment of acute moderate to moderately severe pain.

KP201/APAP was designed with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. We designed KP201/APAP to deter tampering and abuse by selecting a molecular structure that prevents the release of the opioid upon crushing, physical manipulation and other commonly employed extraction techniques. We believe this approach to abuse-deterrence at the molecular level may be more effective than many formulation-based abuse-deterrence technologies, which combine the opioid drug with another drug or use an abuse-deterrent capsule or physical matrix.

In addition to KP201/APAP, KemPharm is building a pipeline of prodrug product candidates that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.